Aerie Pharmaceuticals, Inc. (AERI)
Stock Price:
$12.40 USD
0.10 (0.81%)
Updated Aug 12, 2020 4:00 PM EDT - Market closed
After-hours: $13.01 +0.61 (4.92%) Aug 12, 4:48 PM
Key Info
| Market Cap |
576.78M |
| Revenue (ttm) |
81.58M |
| Net Income (ttm) |
-201.78M |
| Shares Out |
46.51M |
| EPS (ttm) |
-4.42 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 12, 2020 |
| Last Price |
$12.40 |
| Previous Close |
$12.30 |
| Change ($) |
0.10 |
| Change (%) |
0.81% |
| Day's Open |
12.38 |
| Day's Range |
12.03 - 12.66 |
| Day's Volume |
597,330 |
| 52-Week Range |
10.80 - 26.26 |
More Stats
| Market Cap |
576.78M |
| Enterprise Value |
549.83M |
| Earnings Date (est) |
Nov 10, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
46.51M |
| Float |
42.97M |
| EPS (basic) |
-4.41 |
| EPS (diluted) |
-4.42 |
| FCF / Share |
-2.93 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
9.00M |
| Short Ratio |
13.58 |
| Short % of Float |
27.28% |
| Beta |
0.94 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
7.07 |
| PB Ratio |
6.37 |
| Revenue |
81.58M |
| Operating Income |
-179.76M |
| Net Income |
-201.78M |
| Free Cash Flow |
-134.54M |
| Net Cash |
26.95M |
| Net Cash / Share |
0.58 |
| Gross Margin |
51.84% |
| Operating Margin |
-220.36% |
| Profit Margin |
-247.40% |
| FCF Margin |
-164.93% |
| ROA |
-36.28% |
| ROE |
-164.34% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (12)
| Buy |
10 |
| Overweight |
0 |
| Hold |
2 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$28.73*
(131.69% upside)
Low
14.0
Current: $12.40
High
50.0
Target: 28.73
*Average 12-month price target from 11 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | 69.89 | 24.18 | - | - | - | - | - | - | - |
| Revenue Growth | 189.02% | - | - | - | - | - | - | - | - |
| Gross Profit | 65.06 | 23.54 | - | - | - | - | - | - | - |
| Operating Income | -187 | -210 | -146 | -96.87 | -75.09 | -48.13 | -31.15 | -14.98 | -12.97 |
| Net Income | -200 | -233 | -145 | -99.06 | -74.36 | -48.13 | -31.60 | -15.64 | -13.42 |
| Shares Outstanding | 45.43 | 41.66 | 35.32 | 29.14 | 25.78 | 24.09 | 4.96 | 0.95 | 0.93 |
| Earnings Per Share | -4.39 | -5.58 | -4.11 | -3.40 | -2.88 | -2.00 | -6.38 | -16.39 | -14.50 |
| Operating Cash Flow | -150 | -153 | -93.21 | -79.84 | -55.75 | -33.73 | -16.45 | -14.97 | -12.00 |
| Capital Expenditures | -9.96 | -31.31 | -15.97 | -5.08 | -3.28 | -0.18 | -0.06 | -0.05 | -0.05 |
| Free Cash Flow | -160 | -184 | -109 | -84.92 | -59.03 | -33.91 | -16.51 | -15.02 | -12.05 |
| Cash & Equivalents | 309 | 203 | 250 | 234 | 137 | 140 | 69.65 | 2.93 | 15.07 |
| Total Debt | 206 | - | 124 | 124 | 123 | 123 | - | 2.33 | - |
| Net Cash / Debt | 103 | 203 | 126 | 110 | 13.33 | 17.02 | 69.65 | 0.59 | 15.07 |
| Assets | 453 | 285 | 290 | 248 | 159 | 160 | 70.46 | 3.22 | 15.46 |
| Liabilities | 286 | 57.24 | 155 | 143 | 140 | 132 | 3.48 | 6.24 | 3.81 |
| Book Value | 167 | 228 | 136 | 105 | 18.78 | 28.04 | 66.98 | -63.92 | -48.70 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Aerie Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
380 |
| CEO |
Vicente J. Anido |
Stock Information
| Ticker Symbol |
AERI |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Drug Manufacturers - Major |
| Unique Identifier |
NASDAQ: AERI |
| IPO Date |
October 25, 2013 |
Description
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, dry eye, retinal diseases, and other eye diseases. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. The company is also developing AVX-012, a clinical-stage dry eye product candidate; and AR-1105 and AR-13503 sustained-release implants for treating retinal diseases. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.